Invention Application
- Patent Title: NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES
-
Application No.: US17290340Application Date: 2019-11-01
-
Publication No.: US20220002426A1Publication Date: 2022-01-06
- Inventor: Björn FRENDÉUS , Ingrid TEIGE , Linda MÅRTENSSON , Petra HOLMKVIST , Monika SEMMRICH
- Applicant: BIOINVENT INTERNATIONAL AB
- Applicant Address: SE Lund
- Assignee: BIOINVENT INTERNATIONAL AB
- Current Assignee: BIOINVENT INTERNATIONAL AB
- Current Assignee Address: SE Lund
- Priority: EP18203996.6 20181101
- International Application: PCT/EP2019/080003 WO 20191101
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K45/06 ; A61K39/395 ; A61P35/00
Abstract:
Described are novel antibody molecules that specifically bind to TNFR2 on a target cell and thereby agonize TNFR2, but that do not block the ligand TNF-α from binding to the TNFR2. Also described is the use of such antibody molecules in medicine, i.a, in treatment of cancer or chronic inflammatory diseases.
Public/Granted literature
- US12139547B2 Agonistic anti TNFR2 antibody molecules Public/Granted day:2024-11-12
Information query
